United Therapeutics Corporation (UTHR)
Automate Your Wheel Strategy on UTHR
With Tiblio's Option Bot, you can configure your own wheel strategy including UTHR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol UTHR
- Rev/Share 68.2439
- Book/Share 159.0599
- PB 2.4997
- Debt/Equity 0.0
- CurrentRatio 7.2603
- ROIC 0.1507
- MktCap 17981976880.0
- FreeCF/Share 23.7472
- PFCF 16.7899
- PE 14.4366
- Debt/Assets 0.0
- DivYield 0
- ROE 0.1873
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | UTHR | Cantor Fitzgerald | -- | Overweight | -- | $405 | June 2, 2025 |
| Downgrade | UTHR | Wells Fargo | Overweight | Equal Weight | -- | -- | April 25, 2025 |
| Upgrade | UTHR | BofA Securities | Underperform | Neutral | -- | $314 | April 21, 2025 |
News
UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
United Therapeutics hit a record high after its Tyvaso study in idiopathic pulmonary fibrosis met key goals and showed broad patient benefits.
Read More
United Therapeutics: Is UTHR Stock Still A Buy At $400?
Published: September 03, 2025 by: Forbes
Sentiment: Positive
United Therapeutics' stock (NASDAQ: UTHR) surged 33% on September 2nd after the company announced positive late-stage clinical trial results for Tyvaso (treprostinil) Inhalation Solution in idiopathic pulmonary fibrosis (IPF). The trial met its primary endpoint, and the treatment showed good tolerability with a safety profile consistent with prior Tyvaso studies.
Read More
United Therapeutics shares jump on positive lung disease study results
Published: September 02, 2025 by: Proactive Investors
Sentiment: Positive
United Therapeutics Corporation (NASDAQ:UTHR) shares surged more than 35% following the release of positive late-stage clinical trial results for its lung disease drug Tyvaso. The company said its TETON-2 study evaluating nebulized Tyvaso in patients with idiopathic pulmonary fibrosis (IPF) met its primary endpoint, showing significant improvements in lung function compared with placebo over a 52-week period.
Read More
United Therapeutics shares surge on successful late-stage lung disease study
Published: September 02, 2025 by: Reuters
Sentiment: Positive
Shares of United Therapeutics surged over 42% in premarket trading on Tuesday after its lung disease treatment, treprostinil, met the main goal in a late stage study.
Read More
Why Is United Therapeutics (UTHR) Up 11.9% Since Last Earnings Report?
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Positive
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
Read More
United Therapeutics: Critical September IPF Data Catalyst Sets Up Momentous Year
Published: August 27, 2025 by: Seeking Alpha
Sentiment: Positive
United Therapeutics Corporation remains a Buy as it robustly defends its PAH franchise, counters competitive threats, and posts strong Q2 results with double-digit growth. Upcoming TETON-2 data for Tyvaso in IPF in September is a major catalyst; success could secure label expansion and reinforce United's market dominance. Management is confident in Tyvaso's advantages over rivals and is optimistic about ralinepag as a next-generation PAH therapy.
Read More
UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Negative
United Therapeutics' second-quarter earnings miss estimates, while revenues rise 12% on strong Tyvaso and other product sales.
Read More
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Compared to Estimates, United Therapeutics (UTHR) Q2 Earnings: A Look at Key Metrics
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
United Therapeutics (UTHR) Misses Q2 Earnings Estimates
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Negative
United Therapeutics (UTHR) came out with quarterly earnings of $6.41 per share, missing the Zacks Consensus Estimate of $6.8 per share. This compares to earnings of $5.85 per share a year ago.
Read More
United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results
Published: July 30, 2025 by: Business Wire
Sentiment: Neutral
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quarter ended June 30, 2025, driven by continued double-digit year-over-year revenue growth in key products such as Tyvaso DPI, Nebulized Tyvaso, Orenitram, and Unituxin. Total revenues in the second quarter of 2025 grew 12 percent year-over-year to a record $798.6 million, compared to $714.9 million in.
Read More
United Therapeutics (UTHR) Crossed Above the 50-Day Moving Average: What That Means for Investors
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
From a technical perspective, United Therapeutics (UTHR) is looking like an interesting pick, as it just reached a key level of support. UTHR recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
Here's Why United Therapeutics (UTHR) is a Strong Value Stock
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Positive
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension
Published: June 23, 2025 by: Business Wire
Sentiment: Neutral
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced the conclusion of enrollment of the phase 3 ADVANCE OUTCOMES study evaluating the use of an extended-release formulation of ralinepag for the treatment of pulmonary arterial hypertension (PAH). The ADVANCE OUTCOMES study enrolled 728 participants. Clinical worsening events will be accrued through the end of 2025 and top-line data from the st.
Read More
United Therapeutics: Tanking On Rival's PAH Data - I'd Consider Buying Stock
Published: June 11, 2025 by: Seeking Alpha
Sentiment: Negative
United Therapeutics Corporation stock was down substantially yesterday as rival Insmed's PAH data blew the market away. Insmed's treprostinil based product seemingly edged United's Tyvaso on key measures such as pulmonary vascular resistance and 6-minute walk test. United's PAH products account for >90% of its revenues and it already faces a threat from Liquidia's Yutrepia.
Read More
Why Is United Therapeutics (UTHR) Up 9% Since Last Earnings Report?
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
Read More
UTHR Q1 Earnings & Revenues Beat Estimates on Higher Tyvaso Sales
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
United Therapeutics reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven mainly by strong Tyvaso sales.
Read More
United Therapeutics Corporation (UTHR) Q1 2025 Earnings Call Transcript
Published: April 30, 2025 by: Seeking Alpha
Sentiment: Neutral
United Therapeutics Corporation (NASDAQ:UTHR ) Q1 2025 Earnings Conference Call April 30, 2025 9:00 AM ET Company Participants Dewey Steadman - Head of Investor Relations Martine Rothblatt - Chairperson & Chief Executive Officer Michael Benkowitz - President & Chief Operating Officer Leigh Peterson - Executive Vice President, Product Development and Xenotransplantation James Edgemond - Chief Financial Officer & Treasurer Conference Call Participants Joseph Thome - TD Cowen Jessica Fye - JPMorgan Roanna Ruiz - Leerink Andreas Argyrides - Oppenheimer Roger Song - Jefferies Ash Verma - UBS Operator Good morning and welcome to the United Therapeutics Corporation First Quarter 2025 …
Read More
United Therapeutics (UTHR) Reports Q1 Earnings: What Key Metrics Have to Say
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for United Therapeutics (UTHR) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
United Therapeutics (UTHR) Q1 Earnings and Revenues Top Estimates
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
United Therapeutics (UTHR) came out with quarterly earnings of $6.63 per share, beating the Zacks Consensus Estimate of $6.29 per share. This compares to earnings of $6.17 per share a year ago.
Read More
United Therapeutics Corporation Reports First Quarter 2025 Financial Results
Published: April 30, 2025 by: Business Wire
Sentiment: Neutral
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 grew 17 percent year-over-year to $794.4 million, compared to $677.7 million in the first quarter of 2024. “2025 is off to a tremendous start as we reported yet another quarter of record revenue,” said Martine Rothblatt, Ph.D., Chair.
Read More
Here's Why United Therapeutics (UTHR) is a Strong Value Stock
Published: April 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: April 11, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
Published: April 08, 2025 by: Zacks Investment Research
Sentiment: Positive
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
United Therapeutics Corporation (UTHR) Q4 2024 Earnings Call Transcript
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Start Time: 09:00 January 1, 0000 9:31 AM ET United Therapeutics Corporation (NASDAQ:UTHR ) Q4 2024 Earnings Conference Call February 26, 2025, 09:00 AM ET Company Participants Martine Rothblatt - Chairperson and CEO Michael Benkowitz - President and COO James Edgemond - CFO and Treasurer Leigh Peterson - EVP, Product Development and Xenotransplantation Pat Poisson - EVP, Technical Operations Dewey Steadman - Head, IR Conference Call Participants Roger Song - Jefferies Jessica Fye - JPMorgan Ash Verma - UBS Joseph Thome - TD Cowen Roanna Ruiz - Leerink Andreas Argyrides - Oppenheimer Operator Good morning, and welcome to the United …
Read More
About United Therapeutics Corporation (UTHR)
- IPO Date 1999-06-17
- Website https://www.unither.com
- Industry Biotechnology
- CEO Martine A. Rothblatt
- Employees 1305